Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
SAINT LAURENT, Quebec, May 03, 2018 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its first quarter 2018 financial results after market close on May 10, 2018.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Thursday, May 10, 2018
Time: 4:30 p.m. ET
Conference dial-in: (833) 231-8269
International dial-in: (647) 689-4114
Conference ID: 2398086
Webcast Registration: Click here
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
About IntelGenx:
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For more information, please contact: Stephen Kilmer Investor Relations (514) 331-7440 ext 232 [email protected] Or Andre Godin, CPA, CA Executive Vice-President and CFO IntelGenx Corp. (514) 331-7440 ext 203 [email protected]
